Athira Pharma Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
LONA$4.02-10.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
(in thousands, except share amounts)
| Accumulated | ||||||
|---|---|---|---|---|---|---|
| Common Stock · AdditionalPaid-In · OtherComprehensive · Accumulated · TotalStockholders’ | ||||||
| Shares | Amount | Capital | Income (Loss) | Deficit | Equity | |
| Balance as of January 1, 2022 | 37,379,077 | $4 | $417,363 | $(388) | $(95,895) | $321,084 |
| Issuance of common stock upon exercise of common stock options and vesting of restricted stock units | 419,949 | — | 309 | — | — | 309 |
| Issuance of common stock under employee stock purchase plan | 78,361 | — | 345 | — | — | 345 |
| Stock-based compensation | — | — | 10,606 | — | — | 10,606 |
| Unrealized loss on available-for-sale securities | — | — | — | (1,568) | — | (1,568) |
| Net loss | — | — | — | — | (95,639) | (95,639) |
| Balance as of December 31, 2022 | 37,877,387 | $4 | $428,623 | $(1,956) | $(191,534) | $235,137 |
| Issuance of common stock upon exercise of common stock options | 128,534 | — | 167 | — | — | 167 |
| Issuance of common stock under employee stock purchase plan | 166,682 | — | 326 | — | — | 326 |
| Stock-based compensation | — | — | 10,623 | — | — | 10,623 |
| Unrealized gain on available-for-sale securities | — | — | — | 1,607 | — | 1,607 |
| Net loss | — | — | — | — | (117,672) | (117,672) |
| Balance as of December 31, 2023 | 38,172,603 | $4 | $439,739 | $(349) | $(309,206) | $130,188 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.